Nurix Therapeutics (NRIX)
(Real Time Quote from BATS)
$12.67 USD
+0.31 (2.51%)
Updated Apr 29, 2024 11:42 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Nurix Therapeutics, Inc. (NRIX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$24.45 | $35.00 | $14.00 | 97.82% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Nurix Therapeutics, Inc. comes to $24.45. The forecasts range from a low of $14.00 to a high of $35.00. The average price target represents an increase of 97.82% from the last closing price of $12.36.
Analyst Price Targets (11)
Broker Rating
Nurix Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.36 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.36 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, eight are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 72.73% and 18.18% of all recommendations. A month ago, Strong Buy made up 72.73%, while Buy represented 18.18%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 9 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.36 | 1.36 | 1.36 | 1.36 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/17/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
4/11/2024 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Strong Buy |
3/11/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
2/20/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.36 |
ABR (Last week) | 1.36 |
# of Recs in ABR | 11 |
Average Target Price | $24.45 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.72 |